Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Celgene (NASDAQ: CELG) on July 13 and set a price target of $91. The company’s shares closed on Friday at $85.69, close to its 52-week low of $74.13.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 16.7% and a 65.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Sarepta Therapeutics, and Editas Medicine Inc.
Celgene has an analyst consensus of Moderate Buy, with a price target consensus of $119.15, a 39.0% upside from current levels. In a report issued on July 10, Piper Jaffray also maintained a Hold rating on the stock with a $95 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $147.17 and a one-year low of $74.13. Currently, Celgene has an average volume of 6.57M.
Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is neutral on the stock. Most recently, in May 2018, Gilla Kaplan, a Director at CELG sold 27,750 shares for a total of $2,182,538.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company’s products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
Read More on CELG:
